Why is Marksans Pharma falling/rising?

As of 13-Aug, Marksans Pharma Ltd is currently priced at 186.80, showing no change (0.00%). The stock has underperformed its sector by 1.49% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has decreased by 13.34%, and over the past month, it has fallen by 26.63%. Despite a significant increase in delivery volume by 880.3% against the 5-day average, the company faces challenges such as poor long-term growth, with operating profit growth at only 2.87% over the last five years, and a recent decline in PAT by 38.7%. Additionally, while the company has a high management efficiency with a ROE of 17.66% and low debt levels, its valuation appears expensive with a Price to Book Value of 3.4, contributing to the stock's recent struggles.
In the broader market context, the Sensex has remained relatively stable, with only a slight decline of 0.01% over the past week, contrasting sharply with Marksans Pharma's significant drop. The stock's year-to-date performance shows a decline of 36.95%, while the Sensex has gained 3.07% in the same period. This stark difference highlights the challenges faced by Marksans Pharma compared to the overall market, indicating that investor sentiment may be negatively impacted by the company's recent financial results and growth prospects, leading to its underperformance relative to the benchmark.